Irritable bowel syndrome during the epidemic. Observations after 2 years of the COVID-19 pandemic

2021 ◽  
Vol 14 (4) ◽  
pp. 364-368
Author(s):  
Maria Janiak
Keyword(s):  
Irritable Bowel Syndrome ◽  
Outpatient Clinic ◽  
Direct Contact ◽  
Life Quality ◽  
Social Distancing ◽  
Irritable Bowel ◽  
Gastroenterology Outpatient Clinic

Irritable bowel syndrome remains the most frequent cause of patients reporting to gastroenterology outpatient clinic. In the era of COVID-19 pandemic and anxiety, difficult direct contact to their physician, worse experiencing the isolation, expressed in patients’ non-complience to social distancing rules, leads to deterioration of symptoms, and consequently decreased life quality. The multitude of symptoms in patients with irritable bowel syndrome often requires therapy with more than one medication. In the diarrhoea predominant irritable bowel syndrome mebeverine remains useful for over 60 years.

Analysis of the Effect of Sleep Quality on the Life Quality of Irritable Bowel Syndrome Patients

2017 ◽  
Vol 03 (01) ◽  
Author(s):  
Nilufer Uner ◽  
Elif Unsal Avdal ◽  
Berna Nilgun Ozgursoy Uran ◽  
Zehra Ecesoy Akpinar
Keyword(s):  
Irritable Bowel Syndrome ◽  
Sleep Quality ◽  
Life Quality ◽  
Irritable Bowel

SUN-PO147: Life Quality of Patients with Irritable Bowel Syndrome

2019 ◽  
Vol 38 ◽  
pp. S114
Author(s):  
B. Yilmaz ◽  
G. Akbulut ◽  
G. Yurtdaş
Keyword(s):  
Irritable Bowel Syndrome ◽  
Life Quality ◽  
Irritable Bowel

scholarly journals Effectiveness and applicability of low FODMAP diet in the irritable bowel syndrome: Preliminary results of a prospective study

2019 ◽  
pp. 4-9
Keyword(s):  
Irritable Bowel Syndrome ◽  
Prospective Study ◽  
Life Quality ◽  
Treatment Efficiency ◽  
Therapeutic Modalities ◽  
Frequency Survey ◽  
Irritable Bowel ◽  
Fodmap Diet ◽  
A Prospective Study

Abstract: Introduction: Irritable bowel syndrome (IBS) is a very common entity that alters patient’s life quality worldwide. Several therapeutic modalities are available with variable results. Recently, the low-FODMAP diet effect on IBS symptoms has been proven. The aim of our study was to study the efficiency of this diet and to assess its applicability in a Tunisian IBS group of patients. Methods: A longitudinal, prospective study including 34 patients with IBS was conducted. Patients responded to a food frequency survey and had to follow a low FODMAP diet with a dietary guide education for 3 weeks. After the diet, a telephone questionnaire was conducted to evaluate adherence and treatment efficiency. Results: Mean of the population age was 56.5 (21 – 83 years) with a sex ratio of almost 1⁄4. The initial food survey showed a large consumption of white bread and fruits. Tolerance to rich in FODMAP foods was variable among patients. Up to 97% of patients adhered to the low FODMAP diet. A decrease in abdominal pain in 88% of cases and in bloating in 64.7% of cases (p = 0.007) were noted after the diet. Conclusion: In our patients, the low FODMAP diet showed satisfactory results with good adherence, and improvement of IBS symptoms. However, it is important to note the difficulty of a long-term diet in a population with a variable alimentary habit. Key words: low FODMAP diet; irritable bowel syndrome, applicability, Tunisia

scholarly journals FODMAPs Intake of Korean Adult Patients With Irritable Bowel Syndrome

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 854-854
Author(s):  
Woori Na ◽  
Yeji Lee ◽  
Hyeji Kim ◽  
Cheongmin Sohn
Keyword(s):  
Physical Activity ◽  
Irritable Bowel Syndrome ◽  
Life Quality ◽  
General Information ◽  
Dietary Guidelines ◽  
Normal Group ◽  
Activity Level ◽  
Diagnosis Group ◽  
Significant Difference ◽  
Irritable Bowel

Abstract Objectives Irritable bowel syndrome (IBS) is accompanied by abdominal discomfort, stomachache, and diarrhea and deteriorates life quality. Limiting intakes such as Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (FODMAPs) may relieve symptoms. However, studies on FODMAPs intake in Koreans have been conducted very rarely. Therefore, to provide basic data for preparing dietary guidelines for IBS in Koreans, this study was conducted to investigate the FODMAPs intake according to IBS diagnosis. Methods We performed an internet-based survey on 1,000 persons in their 20s-40s living in Korea from April to August 2020. Among them, data of 857 persons (428 men (49.9%)) who gave faithful answers were used for analysis. The survey variables are general information (sex, age, weight, height, gastro-intestinal (GI) related medical history), IBS diagnosis (ROME Ⅲ), dietary assessment (Food Frequency Questionnaire, FFQ), physical activity level (International Physical Activity Questionnaire, IPAQ), and stress-related questions (Brief Encounter Psychosocial Instrument-Korean version, BEPSI-K). Results Among the participants, 186 (21.7%) were diagnosed with IBS, and 671 (78.3%) were normal. Among the IBS diagnosis groups, there were 28 constipation type (15.0%), diarrhea type 66 (35.4%), mixed type 63 (33.9%), and unclassified 29 (15.8%). In the IBS diagnosis group, the GI-related disease history (p < 0.001) and stress (p < 0.001) were significantly higher than the normal group. There was no significant difference in total energy intake, but fat intake was 86.6 ± 55.1 g/day in the IBS diagnosis group and 76.9 ± 47.9 g/day in the normal group (p = 0.014). The total intake of FODMAPs was 13.9 ± 9.9 g/day in the IBS diagnosis group and 12.6 ± 9.7 g/day in the normal group (p = 0.030). Conclusions There was no significant difference in the intake of total FODMAPs according to the IBS subtype. As a result of this study, it is necessary to control fat and FODMAPs to improve IBS patients' symptoms in Korea especially. Funding Sources This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIP).

scholarly journals New methods to the patient management with irritable bowel syndrome

2021 ◽  
Vol 5 (6) ◽  
pp. 391-397
Author(s):  
M.A. Livzan ◽  
◽  
O.V. Gaus ◽  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cortisol Level ◽  
Healthy Subjects ◽  
Patient Management ◽  
Life Quality ◽  
Controlled Study ◽  
Anxiety And Depression ◽  
Control Group ◽  
New Methods ◽  
Irritable Bowel

Aim: to evaluate the efficacy and safety of Kolofort® in the treatment of patients with moderate to mild irritable bowel syndrome (IBS). Patients and Methods: an open cohort prospective placebo-controlled study was conducted with the inclusion of 30 patients (average age 30.7±7.8 years) with an established diagnosis of IBS. The control group consisted of 10 healthy subjects. Kolofort® was prescribed for a course of 12 weeks, 2 tablets 2 times a day. All patients were evaluated before and after the therapy course for the main clinical symptoms of IBS, as well as the severity of anxiety and depression, the level of specific anxiety regarding GIT symptoms and life quality. Cortisol levels in the morning and evening portions of saliva were determined in healthy subjects and patients with IBS. Results: initially, patients with IBS had a high level of anxiety and depression, a high index of visceral hyperssensitivity, and a low life quality. In patients with IBS, the cortisol level in the morning and evening portions of saliva before treatment was statistically significantly higher than in healthy subjects (in both cases, p<0,05). After 12 weeks of therapy, there was a statistically significant decrease in the severity of clinical manifestations of the disease (p<0,05), in the severity of depression, anxiety, visceral hypersensitivity and an increase in the life quality. After the therapy course, patients with IBS noted a significant decrease in the cortisol level in the morning and evening portions of saliva. During therapy, 3 adverse events were registered: headache (n=2), nausea (n=1), which did not require drug discontinuation. Conclusion: the efficacy of Kolofort® in the treatment of patients with IBS with a moderate and mild disease course, both in relation to the main GIT symptoms and concomitant psychoemotional disorders, has been shown. Good efficacy and tolerability of the drug ensured high patient adherence to the treatment. KEYWORDS: irritable bowel syndrome, cortisol, stress, Kolofort, visceral hyperssensitivity, anxiety. FOR CITATION: Livzan M.A., Gaus O.V. New methods to the patient management with irritable bowel syndrome. Russian Medical Inquiry. 2021;5(6):391–397 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-391-397.

Motor and sensory function of the rectum in different types of irritable bowel syndrome

2001 ◽  
Vol 120 (5) ◽  
pp. A399-A399
Author(s):  
J STEENS ◽  
P SCHAAR ◽  
C LAMERS ◽  
A MASCLEE
Keyword(s):  
Irritable Bowel Syndrome ◽  
Sensory Function ◽  
Different Types ◽  
Irritable Bowel
Sign in / Sign up

Export Citation Format

Share Document